🚀 VC round data is live in beta, check it out!
Compugen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Compugen and similar public comparables like SAB Bio, Achieve Life Sciences, Heartseed, Oryzon Genomics and more.
Compugen Overview
About Compugen
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Founded
1993
HQ
Employees
74
Website
Sectors
Financials (LTM)
EV
$128M
Compugen Financials
Compugen reported last 12-month revenue of $56M.
In the same LTM period, Compugen generated $47M in gross profit and $19M in net income.
Revenue (LTM)
Compugen P&L
In the most recent fiscal year, Compugen reported revenue of $73M and EBITDA of $32M.
Compugen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $56M | XXX | $73M | XXX | XXX | XXX |
| Gross Profit | $47M | XXX | $64M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | — | XXX | $32M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 44% | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 43% | XXX | XXX | XXX |
| Net Profit | $19M | XXX | $35M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 49% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Compugen Stock Performance
Compugen has current market cap of $271M, and enterprise value of $128M.
Market Cap Evolution
Compugen's stock price is $2.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $128M | $271M | 3.0% | XXX | XXX | XXX | $0.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCompugen Valuation Multiples
Compugen trades at 2.3x EV/Revenue multiple, and 4.0x EV/EBITDA.
EV / Revenue (LTM)
Compugen Financial Valuation Multiples
As of April 18, 2026, Compugen has market cap of $271M and EV of $128M.
Equity research analysts estimate Compugen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Compugen has a P/E ratio of 14.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $271M | XXX | $271M | XXX | XXX | XXX |
| EV (current) | $128M | XXX | $128M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBIT | 8.7x | XXX | 4.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 14.5x | XXX | 7.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Compugen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Compugen Margins & Growth Rates
Compugen's revenue in the last 12 month declined by (64%).
Compugen's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.
Compugen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (64%) | XXX | (80%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (321%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42% | XXX | 31% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Compugen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Compugen | XXX | XXX | XXX | XXX | XXX | XXX |
| SAB Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Achieve Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Heartseed | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adagene | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Compugen M&A Activity
Compugen acquired XXX companies to date.
Last acquisition by Compugen was on XXXXXXXX, XXXXX. Compugen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Compugen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCompugen Investment Activity
Compugen invested in XXX companies to date.
Compugen made its latest investment on XXXXXXXX, XXXXX. Compugen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Compugen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Compugen
| When was Compugen founded? | Compugen was founded in 1993. |
| Where is Compugen headquartered? | Compugen is headquartered in Israel. |
| How many employees does Compugen have? | As of today, Compugen has over 74 employees. |
| Who is the CEO of Compugen? | Compugen's CEO is Eran Ophir. |
| Is Compugen publicly listed? | Yes, Compugen is a public company listed on Nasdaq. |
| What is the stock symbol of Compugen? | Compugen trades under CGEN ticker. |
| When did Compugen go public? | Compugen went public in 2000. |
| Who are competitors of Compugen? | Compugen main competitors are SAB Bio, Achieve Life Sciences, Heartseed, Oryzon Genomics. |
| What is the current market cap of Compugen? | Compugen's current market cap is $271M. |
| What is the current revenue of Compugen? | Compugen's last 12 months revenue is $56M. |
| What is the current revenue growth of Compugen? | Compugen revenue growth (NTM/LTM) is (64%). |
| What is the current EV/Revenue multiple of Compugen? | Current revenue multiple of Compugen is 2.3x. |
| Is Compugen profitable? | Yes, Compugen is net-income-positive (as of the last 12 months). |
| What is the current net income of Compugen? | Compugen's last 12 months net income is $19M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.